Actos, Pioglitazone News

Takeda Pharmaceutical Co. , maker of the worlda s best-selling diabetes drug, agreed to pay as much as $1 billion to Amylin Pharmaceuticals Inc.

In a randomized, double-blind, placebo-controlled trial of 247 patients who had NASH but not diabetes, pioglitazone improved key histological features and liver enzymes; however, vitamin E was more successful for the treatment of NASH in these patients.

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met as initial therapy reached the study goal of hemoglobin A1c of less than or equal to 7 percent compared to either component alone.

Buy Actos Online. Order Cheap Actos without prescription in Professional Pharmacy Store - Wikio >> Drug Uses Actos is used for treatment of type 2 diabetes in certain patients.

Takeda is to set up four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg as part of its strategic global expansion effort.

Main Category: Diabetes Also Included In: Clinical Trials / Drug Trials ; Conferences Article Date: 01 Oct 2009 - 2:00 PDT InteKrin Therapeutics Inc.

Takeda Pharmaceutical Company Limited announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg.

Q: I heard that a new oral drug for diabetes was approved. What can you tell me about it? A: The FDA recently approved Onglyza for the treatment of people with type 2 diabetes.

DEERFIELD,A Ill. A subsidiary of a Japan-based pharmaceutical company received a complete response letter from the Food and Drug Administration regarding a drug designed to control glucose levels in diabetes patients.

Type 2 diabetes mellitus is commonly associated with both microvascular and macrovascular complications and a strong correlation exists between glycaemic control and the incidence and progression of vascular complications.

Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS for the Treatment of Type 2 Diabetes Submitted by admin on 9/4/2009 @ 12:00 AM Companies mentioned in this article: Takeda Pharmaceutical Company Limited DEERFIELD, Ill.

OBJECTIVE: To compare the risk of acute myocardial infarction, heart failure, and death in patients with type 2 diabetes treated with rosiglitazone and pioglitazone.

A study just published on bmj.com reports that rosiglitazone, a drug used to treat type 2 diabetes , is linked with an increased risk of heart failure and death among elder patients compared to pioglitazone, which is a similar drug.

Rosiglitazone, brand name Avandia, has higher rates of heart failure and death than similar alternative Scientists say doctors should stop prescribing a commonly used diabetes drug, after studies show that it is linked to higher rates of heart failure and death than a similar alternative.

Main Category: Diabetes Also Included In: Heart Disease ; Cardiovascular / Cardiology Article Date: 19 Aug 2009 - 13:00 PDT Rosiglitazone, a drug used to treat type 2 diabetes , is associated with an increased risk of heart failure and death among older patients compared to a similar drug , concludes a study published on bmj.com today.

Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug , concludes a study published on bmj.com today.

ACTOS to be marketed by Takeda in Canadian Market MISSISSAUGA, ON, Aug. 21 /CNW/ - Takeda Canada, Inc.

A DRUG to treat patients with Type 2 diabetes is linked to an increased risk of heart failure and its continued use may not be justified, a study said yesterday.

The type 2 diabetes drug Avandia increases the risk of heart failure and death more than another drug in the same class, Actos , new Canadian research contends.

New research involving nearly 40,000 Ontario patients is questioning the use of a widely prescribed diabetes drug that an expert in drug safety says should be removed from the market Photograph by: Bill Keay, Vancouver Sun New research involving nearly 40,000 Ontario patients is questioning the use of a widely prescribed diabetes drug that an ...